Phase I/II study to evaluate systemic durvalumab plus intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results.-MedSci.cn

Phase I/II study to evaluate systemic durvalumab plus intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results.

Zamarin, D; Odunsi, K; Slomovitz, BM; Duska, LR; Nemunaitis, JJ; Reilley, M; Bykov, Y; Holland, A; Hubbard-Lucey, VM; Shohara, L; Schwarzenberger, P; Ricciardi, T; Macri, MJ; Ryan, A; Jaderberg, ME; Venhaus, RR

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务